The U.S. Court of Appeals for the Federal Circuit has affirmed the validity of a patent held by Takeda Pharmaceuticals for a dissolvable acid reflux medication, but held a generic alternative does not infringe the patent.
Prevacid SoluTab allows a patient to dissolve the medication in their mouth before swallowing it. Takeda specialized the medication by enhancing its dissolution into small enough granules to prevent patients from suffering a rough feeling on their throat as they swallow it.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
